Detalhe da pesquisa
1.
Quality of life in patients with cancer during the COVID-19 pandemic - a Danish cross-sectional study (COPICADS).
Acta Oncol
; 60(1): 4-12, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33031010
2.
A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.
BMC Cancer
; 16: 91, 2016 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26867764
3.
New use for old drugs: Epirubicin in colorectal cancer.
Acta Oncol
; 60(7): 954-956, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33783307
4.
The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer.
BMC Genomics
; 16: 404, 2015 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-25997618
5.
Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab.
Int J Cancer
; 137(10): 2470-7, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25664394
6.
What is long-term survival in patients with peritoneal metastasis from gastric, pancreatic, or colorectal cancer? A study of patients treated with systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC).
Pleura Peritoneum
; 8(4): 147-155, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38144215
7.
Importance of biopsy site selection for peritoneal regression grading score (PRGS) in peritoneal metastasis treated with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC).
Pleura Peritoneum
; 7(3): 143-148, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36159216
8.
TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.
Oncotarget
; 7(37): 59441-59457, 2016 Sep 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-27509063
9.
Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance.
Mol Oncol
; 9(6): 1169-85, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25759163
10.
Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.
PLoS One
; 9(2): e87746, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24498368
11.
Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.
PLoS One
; 9(10): e109430, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25329796
12.
High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.
Mol Oncol
; 7(3): 637-46, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23506979